Amphastar Pharmaceuticals (AMPH) PT Raised to $23 at Jefferies
Jefferies raised its price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $23.00 (from $19.00) while maintaining a Buy rating.
Analyst David Steinberg notes revenue for the quarter came in slightly above their estimates at $57.9M largely due to better than expected Naloxone revs. The EPS beat was partially due to lower R&D spend.